Holds one active US DMF for anagrelide, filing since 2003. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 9 markets.
Holds one active US DMF for anagrelide, filing since 2015. Its 2026 FDA inspection closed as NAI, and its GMP is recognised in 20 markets.
Holds one active US DMF for anagrelide, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 20 markets.
Holds one active US DMF for anagrelide, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 10 markets.
Holds one active US DMF for anagrelide, filing since 2002. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds one active US DMF for anagrelide, filing since 2003. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds one active US DMF for anagrelide, filing since 2002.
The names are listed below. Ask Fred about the filings, inspection history and GMP certificates on record for each manufacturer.
Chat with Fred, your AI analystContract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Ask Fred which manufacturers are on record for anagrelide and what filings they hold.
Chat with Fred, your AI analyst